Race Oncology
Update in progressRAC.AX (ASX)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Racura Oncology Ltd is a Phase 3 cancer biopharma focused on advancing its lead asset, RCDS1 (E,E-bisantrene), a small-molecule that binds G4-DNA and RNA to inhibit the cancer growth regulator MYC. Its proprietary RC220 formulation is in Phase 3 for acute myeloid leukemia, with Phase 1/1b programs in EGFRm NSCLC and in combination with doxorubicin. It collaborates with Astex, MD Anderson, Sheba, UNC, and universities in Australia. Formerly Race Oncology Ltd, renamed in Dec 2025. Founded 2011, based in Sydney.
Company score
- Sentiment
- 0.42
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.28
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!